<DOC>
	<DOCNO>NCT02020629</DOCNO>
	<brief_summary>In hypoglycemia , counterregulation restore glucose level . An important part counterregulation release hormone glucagon . Since GLP-1 receptor agonist lixisenatide show associate low risk hypoglycemia , study examines whether lixisenatide affect glucagon response hypoglycemia .</brief_summary>
	<brief_title>Study Lixisenatide Counterregulation Hypoglycemia</brief_title>
	<detailed_description>The study single-center , randomize , placebo-controlled study cross-over design examines glucagon response hyperinsulinemic hypoglycemic phase 6-week treatment lixisenatide ( placebo ) add-on basal insulin metformin . The hypothesis study glucagon counterregulation hypoglycemia patient treat lixisenatide basal insulin low patient treat basal insulin .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Hypoglycemia</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<criteria>1 . Male , nonfertile female female childbearing potential use medically approve birth control method age &gt; 18 year . 2 . Adult patient type 2 diabetes treat basal insulin ( NPH insulin , insulin detemir , insulin glargine insulin degludec ) ( stable insulin dose ( ±10 % ) last three month ) concomitant &gt; 3 month stable dose ( &gt; 1500 mg daily ) metformin . 3 . HbA1c &lt; 10 % ( DCCT standard ; &lt; 83 mmol ( mol ) visit 1 . 1 . Treatment antihyperglycemic agent apart basal insulin metformin , i.e. , bolus insulin antihyperglycemic oral agent apart metformin 2 . Type 1 diabetes ( include LADA ) 3 . Pregnant lactate female . Women childbearing potential effective contraceptive method . Acceptable contraceptive include contraceptive sponge ; hormonal contraception pill , patch , vaginal ring , injectable contraceptive ; intrauterine device . Women childbearing potential ( premenopausal , surgically sterile woman least 3 month prior time screen ) must confirm negative serum pregnancy test screen visit . They must use effective contraceptive method throughout study , agree repeat pregnancy test designate visit . The applied method contraception meet criterion highly effective method birth control accord `` Note guidance nonclinical safety study conduct human clinical trial pharmaceutical ( CPMP/ICH/286/95 ) '' 4 . A history secondary form diabetes , e.g. , Cushing 's syndrome acromegaly . 5 . Acute infection may affect blood glucose control within 4 week prior visit 1 6 . Any history recent ( &lt; 2 week ) recurrent severe hypoglycemic episode hypoglycemia unawareness 7 . Donation one unit ( 500 ml ) blood , significant blood loss equal least one unit blood within past 2 week blood transfusion within past 8 week . 8 . Treatment growth hormone oral parenteral corticosteroid ( &gt; 7 consecutive day treatment ) within 8 week prior visit 1 thereafter whole study period . 9 . Use investigational drug within 30 day prior visit 1 . 10 . Laboratory finding time screening , include amylase and/or lipase &gt; 3 time upper limit normal laboratory range ( ULN ) Pcalcitonin ≥20 pg/ml ( 5.9 pmol/L ) . 11 . Personal immediate family history medullary thyroid cancer ( MTC ) genetic condition predisposes MTC ( e.g . multiple endocrine neoplasia syndrome ) . 12 . History unexplained pancreatitis , chronic pancreatitis , pancreatectomy , stomach/gastric surgery 13 . Allergic reaction GLP1 receptor agonist metacresol 14 . Clinically relevant history gastrointestinal disease associate prolonged nausea vomiting , 15 . Cardiovascular , hepatic , neurological , endocrine disease , active malignant tumor major systemic disease patient short life expectancy make implementation protocol interpretation study result difficult .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Glucagon</keyword>
	<keyword>Hypoglycemia</keyword>
	<keyword>Counterregulation</keyword>
</DOC>